Latest News

The consensus analyst price target for NatWest Group has seen a slight upward revision, increasing marginally from £5.92 to £5.99. This subtle change reflects growing optimism among analysts, spurred by underlying earnings momentum and expectations of future profitability. Read on to discover how investors can stay informed about the evolving narrative surrounding NatWest Group’s performance and outlook. What Wall Street Has Been Saying Recent research coverage on NatWest Group has shown a...

If you have been watching China Taiping Insurance Holdings and wondering whether now is the right time to act, you are far from alone. Its recent share price journey has been nothing short of eventful. Over the past month, the stock pulled back by 22.5%, giving some investors pause. If we zoom out, the bigger picture looks much brighter: China Taiping’s shares are up 33.7% year-to-date and have surged a remarkable 144.0% over the past three years. Even after a softer week, the stock is still...

If you have STERIS stock in your portfolio, or you are considering adding it, it is hard not to notice how its performance stands out lately. The company’s shares closed recently at $249.23, and while the past week brought a modest 0.5% gain, the last month was a bit softer, down just 1.0%. Zoom out, and things look much more impressive: STERIS is up 23.1% so far this year, and over the past three years, the stock has soared 59.7%. Even its five-year return sits at an impressive 51.0%, more...

If you’ve been eyeing Hain Celestial Group (HAIN) lately, the recent shake-up in its Garden Veggie Snacks line is probably grabbing your attention. The brand’s biggest recipe overhaul ever, featuring avocado oil snacks, sweet potato straws, and revamped packaging, hits Target shelves soon and aims firmly at parents and kids with a promise of healthier, tastier options. But investors know there’s more to the story, especially since this announcement landed alongside deeply negative earnings...

Cettire Limited (ASX:CTT) was recently added to the S&P/ASX Emerging Companies Index, highlighting its growing profile within the Australian equities landscape. This index inclusion can often result in greater institutional and retail investor interest as index-tracking funds adjust portfolios, potentially impacting future trading volumes and visibility. We'll explore how becoming part of a widely tracked index can influence Cettire's business outlook and investment narrative. Uncover the...

Paychex shares saw a modest adjustment in analyst consensus price target, dipping slightly from $146.58 to $145.08. This subtle shift reflects recent concerns over slowed growth and uncertainty in fiscal guidance, as well as choppy economic data. Stay tuned to learn how you can monitor ongoing changes to the Paychex investment story as the narrative develops. What Wall Street Has Been Saying Analysts covering Paychex have weighed in on the stock's prospects, with opinions broadly divided...

Unisys stock's consensus analyst price target has recently dropped from $7.67 to $6.75, marking a notable shift in sentiment. While revenues remain stable and new business wins point toward growth, analysts appear divided over the pace and reliability of further progress. Stay tuned to find out how these evolving developments might reshape the outlook and how you can keep track of the ongoing shifts in the Unisys story. What Wall Street Has Been Saying Analyst sentiment on Unisys stock...

In recent weeks, Corporate Travel Management was suspended from the Australian Stock Exchange after disclosing accounting irregularities that prompted a delay in releasing its financial results and ongoing investigations by Deloitte and KPMG. This development puts a spotlight on financial transparency and the importance of timely, accurate reporting within the travel services sector, especially as the company manages a substantial £550 million UK government contract. We'll examine how the...

Trying to figure out what to do with Pilbara Minerals’ stock right now? You’re not alone. Over the past month, the share price has bounced back, climbing over 11.6%. That jump follows a 6.6% rise just this past week, hinting that investors might be spotting new reasons for optimism, or maybe they’re rethinking the risks around lithium exposure in today’s shifting market. Of course, the bigger picture includes some sobering moves: a 1-year dip of 18.3%, and a steeper 44% slide over 3 years,...

Thinking about whether to hold or buy more Compagnie de l'Odet stock this year? You are definitely not alone. Over the past few years, this French conglomerate has kept investors on their toes, thanks in part to its quietly impressive long-term story. Despite wider market swings and shifting investor sentiment, the stock has delivered a remarkable 108.2% growth over the last five years. But before you get too comfortable, the ride has not been all smooth. The past year has seen shares drop by...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

If you have been eyeing MEG Energy and wondering whether now is the right time to make a move, you are not alone. This stock has had quite a journey, turning heads with a staggering 961.4% return over the past five years. Even if you zoom in a little closer, the numbers are impressive: up 94.8% over three years, with a healthy 18.0% gain year to date. Yet, the recent mood has been a touch more cautious, with the stock dipping -2.4% over the past week, despite not much in the way of major news...

What are the early trends we should look for to identify a stock that could multiply in value over the long term...

Thinking about what’s next for First International Bank of Israel stock? You’re not alone. With a stellar 53.4% gain over the past year and an astonishing 301.6% surge over the last five years, plenty of investors are wondering if there’s still room to run or if things are getting a bit overheated. The recent 21.7% jump year-to-date reflects ongoing optimism. However, there was a minor pullback this past month, down 4.6%, and a slight dip of 1.4% over the last week. These short-term changes...

AMFI (OTCPK:AFIP.A) may not always grab headlines, but its recent moves in the market have investors wondering what the next chapter might hold. There’s no major headline event or explosive news to explain recent activity, and that in itself brings an intriguing question: is the current share price momentum sending a subtle signal, or is it simply business as usual for a company flying under the radar? Looking at the past few months, AMFI’s share price hasn’t budged—flat over the past week...

Guardant Health's consensus analyst price target saw only a slight increase in the most recent update, moving from $61.33 to $62.41. This relatively stable price expectation reflects strong revenue momentum and continued leadership in liquid biopsy technology. It also shows tempered optimism following recent clinical data results. Read on to discover what is driving these perspectives and how you can stay informed about evolving developments for Guardant Health moving forward. What Wall...

DUG Technology (ASX:DUG) just gave markets plenty to talk about. In a double dose of news, the company announced the quotation of 436,738 new ordinary shares on the ASX, aimed at boosting liquidity and broadening its reach. Additionally, it secured the first purchase order from Petronas under a multi-year contract, with the overall value of the deal climbing higher than first expected. For investors keeping an eye on the tech sector, these moves signal a company actively expanding both its...

If you’ve been tracking Aura Minerals (TSX:ORA) lately, you likely noticed the recent excitement after the company announced it hit commercial production at its Borborema gold mine. With the mill now running above 80% of its design capacity and gold recoveries climbing past 90%, this moment marks a tangible boost for Aura’s future production profile. Investors watching for concrete signs that Aura can deliver on its ambitious growth promises finally have a new data point to factor into their...

Avadel Pharmaceuticals recently saw its consensus analyst price target edge up slightly from $20.20 to $20.30, reflecting a largely steady outlook. This minimal change is rooted in a balance between optimism over Lumryz’s commercial momentum and lingering concerns about ongoing competition in the sleep disorder market. Read on to discover how you can stay informed about ongoing shifts in the stock's narrative as new developments unfold. What Wall Street Has Been Saying Analyst commentary on...

Cellebrite DI's consensus analyst price target has seen a modest uptick, rising from $22.57 to $23.14 despite several headwinds. While lingering softness in the U.S. federal market and revised revenue estimates have tempered enthusiasm, analysts attribute much of this to deal timing delays rather than a loss of demand. Stay tuned to find out how you can track ongoing developments in Cellebrite DI's evolving story. What Wall Street Has Been Saying Analyst coverage of Cellebrite DI reflects a...

Silvercorp Metals stock has recently seen its consensus analyst price target rise from CA$8.38 to CA$8.76, reflecting a renewed sense of optimism among market watchers. This uptick is driven by expectations of production growth, leverage to stronger silver prices, and the upcoming diversification of assets. Read on to discover how you can follow these evolving developments and stay informed about Silvercorp Metals’ shifting narrative. What Wall Street Has Been Saying Analyst coverage of...

On September 23, 2025, NORMA Group SE issued revised earnings guidance, lowering its expected group sales from continuing operations for the year to approximately €810 million to €830 million, down from its previous estimate, which included Water Management, of around €1.1 billion to €1.2 billion. This updated forecast reflects NORMA Group’s realignment of its business focus and the anticipated effects of its divestment of the Water Management unit, offering insight into management’s current...

There has not been a particular event sending shockwaves through Arjo (OM:ARJO B) shares this week, but sometimes a quieter period can be just as interesting. Investors keeping an eye on the medical technology maker may be wondering if recent market movements signal something deeper, such as shifting expectations for growth or profitability. Valuation becomes an important consideration, especially as the company continues to recalibrate in a changing healthcare environment. Taking a step...

When researching a stock for investment, what can tell us that the company is in decline? Typically, we'll see the...